Back to search
H20-HEALTH-Health, demographic change and wellbeing
Soraprazan - a new regenerative therapy for Stargardt's disease
Awarded: NOK 14.6 mill.
Source:
Project Manager:
Project Number:
779317
Application Type:
Project Period:
2017 - 2021
Funding received from:
Organisation:
Soraprazan - a new regenerative therapy for Stargardt's disease
Soraprazan – a new regenerative therapy for Stargardt’s disease Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.
Funding scheme:
H20-HEALTH-Health, demographic change and wellbeing
2.4BILL. NOKtotal funding in the programme period137PROJECTShave received funding in the programme period1SOURCEhas financed the programme
Funding Sources
Thematic Areas and Topics
HelseBransjer og næringerHelsenæringenAnvendt forskningInternasjonaliseringLTP3 Et kunnskapsintensivt næringsliv i hele landetHelseKlinisk forskningPolitikk- og forvaltningsområderHelse og omsorgInternasjonaliseringInternasjonalt prosjektsamarbeidPortefølje HelseLTP3 Styrket konkurransekraft og innovasjonsevnePortefølje ForskningssystemetUtviklingsarbeidPolitikk- og forvaltningsområderLTP3 HelseBransjer og næringerPortefølje Innovasjon